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Epidemiologists have predicted that viral infections might 
spread fast in our highly globalized world. For example, a 
report on “Preparedness for a high-impact respiratory patho-
gen pandemic” was published in September 2019 by Johns 
Hopkins Centre for Health Security [1]. This report ranked 
aerosol transmitted viral diseases as the highest risk for a 
wide-spreading pandemic and named, as an example beyond 
influenza, also severe acute respiratory syndrome (SARS) 
as a zoonotic coronavirus. In approximately 1 year, SARS-
CoV-2 (coronavirus type 2) has developed into a true pan-
demic and reminds us that problems must be taken seriously 
in a timely manner. In the case of the current coronavirus 
disease 2019 (COVID-19), we profited from the protocols 
established during earlier pandemics. Following the influ-
enza (H1N1) pandemic in 2009, a pandemic preparedness 
plan was developed by the World Health Organization 
(WHO). SARS-CoV infections in 2003 and MERS (Mid-
dle East Respiratory Syndrome) in 2012 lead to research in 
this type of Coronaviridae and strategies to combat them. 
The Ebola epidemic in West Africa 2014–2016 activated a 
push for programs in preventive and therapeutic strategies 
driven by governmental and non-governmental institutions. 
We now profit from many of these efforts by building on 
SARS biological and medical research anti-viral compound 
candidates and the fastest ever approved vaccine develop-
ments in history so far. A lesson to learn from this pandemic 
could be that preparedness may reduce the impact of disas-
ters, and spending money on contingency measures may be 
well invested.
For the moment, viral infections are present in our minds. 
However, the awareness the COVID-19 pandemic has cre-
ated for infectious diseases should go beyond the current 
threat of this new coronavirus. Even today, COVID-19 is 
the most prominent but by far not the only actual infectious 
disease outbreak (Fig. 1).
The coevolution of potentially pathogenic organisms with 
humans and our environment sets the basis for a continuing 
battle. A list of human pathogens, reaching a total of 2107, 
was gathered in 2008 (ranked by the number of species: 
approximately 1000 bacteria, 440 fungi, 300 helminths, 
270 viruses, and 80 protozoa) [2]. Certain regions in the 
world have a higher burden of zoonotic infectious disease 
occurrence, originating from their higher biodiversity [3]. 
Unfortunately, in some regions, this risk is correlated with 
limited resources to prepare against such threats. Most path-
ogens have a low spreading tendency and often, for vector 
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or climate reasons, become endemic only in some regions 
of the world. However, changes in natural habitats, climate 
change, and human mobility affect the global distribution 
of pathogens. Infectious diseases are a global threat and 
challenge, which should be tackled promptly and in unison 
across the world. The sporadic emergence of new human 
pathogens shifts in geographic distributions, and on top of 
this, the development of antimicrobial (antibiotics, antivi-
ral, antifungal, and antiparasitic actives) resistance empha-
sizes the urgent need to maintain and intensify our efforts 
in anti-infective research to ensure as much preparedness as 
possible. Not only the appearance of new human pathogens 
is an issue but climate change can contribute to increased 
incidence or shifts in geographical distribution (for exam-
ple, Zika or Dengue viruses transmitted by mosquitoes, or 
Borrelia burgdorferi by ticks). In today’s world, infectious 
diseases are a leading cause of death worldwide, particularly 
in low- to middle-income countries, and especially in young 
children. Lower respiratory tract infections (e.g., pneumo-
nia, also including chronic obstructive pulmonary disease 
(COPD) and influenza) are still in the top-ten killer diseases 
worldwide, particularly high in ranking in low-income coun-
tries accompanied in that list by diarrheal diseases, malaria, 
and tuberculosis (Table 1) [4]. The number of deaths from 
lower respiratory infections declined between 2000 and 
2019, as well as the impact of diarrheal diseases, tubercu-
losis, and HIV/AIDS. However, because of rising antimi-
crobial resistance, the COVID-19 pandemic and economic 
crises, the threat of a reversal in this decline in death rate 
from such infectious diseases is imminent.
Our medications against pathogens are losing their effi-
cacy for various species. Tuberculosis and malaria are major 
Fig. 1  Word cloud published by the International Society of Infec-
tious Diseases (ISID) for the reported disease outbreaks in the year 
2019 (left) and quarter three of 2020 (right). Word size is an indica-
tion of the frequency of ProMED reports. ISID provides global sur-
veillance of infectious diseases (https:// isid. org/ surve illan ce/). Despite 
the prominent role of COVID-19 in 2020, there is still a multitude of 
other infectious disease outbreaks
Table 1  The top ten leading 
causes of death ( source: 
WHO Report 2020). Infectious 
diseases are highlighted in bold
Rank Low-income countries High-income countries Worldwide
1 Neonatal conditions Ischemic heart disease Ischemic heart disease
2 Lower respiratory infections Alzheimer’s disease Stroke
3 Heart disease Stroke Chronic obstructive pulmonary 
disease (COPD)
4 Stroke Lung cancers Lower respiratory infections
5 Diarrheal diseases COPD Neonatal conditions
6 Malaria Lower respiratory infections Lung cancers
7 Road injury Colon cancers Alzheimer’s disease and dementias
8 Tuberculosis Kidney diseases Diarrheal diseases
9 HIV/AIDS Hypertensive heart disease Diabetes
10 Cirrhosis of the liver Diabetes Kidney diseases
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killer diseases with severe resistance problems. Importantly, 
several bacterial human pathogens (especially the six highly 
virulent pathogens Enterococcus faecium, Staphylococcus 
aureus, Klebsiella pneumoniae, Acinetobacter baumannii, 
Pseudomonas aeruginosa, and Enterobacter species, a.k.a. 
ESKAPE) show a rising tendency of antimicrobial resistance 
(AMR) and spread not only in the hospital environment but 
also through community transmission. An estimated 700,000 
deaths worldwide, thereof alone 230,000 from multidrug-
resistant (MDR) tuberculosis, are claimed by AMR today 
[5]. Drug-resistant microbes endanger populations with poor 
sanitation as well as surgical inventions in developed coun-
tries’ clinics. Therefore, worldwide calls have been issued 
to develop new anti-infectives and use the existing ones with 
more caution. One hundred and twenty-seven countries have 
developed a national action plan to tackle AMR [6].
Does this not mainly concern sanitation councils and drug 
discovery research? Is this actually a topic for drug delivery 
scientists? Undoubtedly, strategies for better disease preven-
tion and responsible use of anti-infectives are needed along 
with the discovery and development of novel active com-
pounds. However, research for better anti-infective medi-
cines also deserves to be a topic in drug delivery. Figure 2 
provides an overview of anti-infective strategies now clearly 
going beyond classical antibiotic small molecule therapies. 
The diversity of actives used in such therapeutic concepts 
can profit from various delivery systems and formulations. 
Drug delivery can enable safer vaccines based on proteins or 
nucleotides. This will enable vaccination against pathogens 
so far not suitable or highly complicated for vaccination by 
killed or attenuated microorganisms because of their high 
genetic variability, the spread of multiple serogroups/types, 
or complications by preexisting immune responses for simi-
lar viral families (like HIV or dengue virus). Reverse vac-
cinology can identify optimized epitope display by broad 
HLA groups, and biotechnology allows engineering of 
immunogens and production of glycoproteins and construc-
tion of epitope-optimized proteins, or nucleotide sequences 
encoding them (pDNA, mRNA, or self-replicating RNAs). 
The key to vaccination is the delivery of antigens with opti-
mized antigen presentation to achieve a sufficient broad pro-
tective immune response [7]. Thus, the combined efforts of 
understanding the disease (pathogen life cycle and immune 
response), bioinformatics, biotechnology, and delivery can 
be optimized through existing “platform technologies” for 
vaccine development including mRNA-based, virus-like-
particle-based, and viral-vector-based vaccines. The speed 
in SARS-CoV-2 vaccine development was due to the invest-
ment in such platform technologies before the emergence 
of the virus and the already outlined plans for regulatory 
approval plans in a pandemic emergency. Such vaccine 
platform technologies, no matter whether viral- or non-
viral delivery, predetermine the immune response type and 
safety considerations and allow alignment of manufactur-
ing procedures. A technology that allows a broad range of 
antigens to be engineered with moderate technology adapta-
tion such as the mRNA platform can be a game changer in 
the development effort for vaccines. The non-profit research 
Fig. 2  Anti-infective strategies are getting more diverse, comprising 
many concepts in development pipelines. They span from disease 
prevention via vaccination, strategies treating the host or the host 
microbiota, or modulation of the pathogenicity of microbes to anti-
microbials by single active or combinations. *FMT = fecal microbiota 
transplantation. **Resistance inhibitors are lactamase-inhibitors, per-
meabilizers, or efflux-pump inhibitors
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organization IAVI with a long tradition in vaccination 
recently announced the first results of their clinical trial of an 
HIV vaccine in phase 1 [8]. The key to this success was the 
identification of broadly neutralizing antibodies, targeting a 
specific B lymphocyte population, and the use of delivery 
platforms (currently replicating not only viral vector vesicu-
lar stomatitis virus but also mRNA) [9].
Prevention of infections reduces the need for antibiot-
ics, a strategy that is not limited to humans, but also can 
decrease antibiotic use in animals. Reducing the use of 
antibiotics in animal housing and food production is an 
essential piece of the strategy against AMR. A sufficiently 
high concentration of anti-infectives is essential to be effec-
tive and prevent the development of drug resistance. Drug 
delivery can ensure delivery of the right dose to the target 
at the right time for as long as is necessary. Optimizing bio-
availability and pharmacokinetics by the dosage form is a 
classical theme in drug delivery and may contribute a lot 
to minimizing the risk of resistance development. Targeted 
delivery strategies could open the therapeutic window for 
drugs previously considered too toxic for systemic deliv-
ery (e.g., colistin in some pulmonary applications [10, 11]. 
Delivery strategies/systems, ensuring effective doses, and 
reducing adverse effects are needed. Improved delivery and 
synergistic combinations might increase the time we can use 
existing antibiotics, an important issue given the challenges 
in the discovery of novel antibiotics. Gained knowledge on 
the pathogen mechanisms (e.g., biofilm communication, 
efflux pumps, molecules interfering with the host immune 
response) of certain bacteria of high antibiotic-resistance 
tendency that can be used as anti-infective targets. Some 
modern anti-infectives, like e.g., quorum-sensing inhibitors, 
do not aim for killing to reduce evolutionary pressure and 
therefore are referred to better as pathoblockers rather than 
antibiotics. However, because they must reach intracellular 
targets, their bioavailability at the site of action is much lim-
ited by the permeability across the bacterial cell envelope 
(“cell wall”) especially in case of gram-negatives [12].
While research on advanced delivery technologies has 
concentrated for a long time on oncology, the last few 
years saw an increase in delivery approaches to improve 
anti-infective therapies. Some were mainly transferring 
developed particle technology to other diseases, but sophis-
ticated approaches for highly tailored systems using bacte-
rial enzymes to trigger drug release, mimicking pathogen 
entry paths, or interfering with biofilm growth mode have 
also been developed. Achieving selectivity in antimicrobi-
als might be supported by carrier systems. Attempts to use 
nucleotides as anti-infectives with the possibility of high 
selectivity to kill or modify bacteria are promising new 
concepts, but it need strategies for delivery into bacterial 
cells. Host-directed therapies, e.g., to limit cytokine storms 
and tissue damage in viral infections may be realized by 
delivery strategies for biomacromolecules. Non-invasive 
antibody delivery at mucosal barriers as a preventive strat-
egy is suggested. There are many possibilities for delivery 
technologies, and several examples are reported in this spe-
cial issue, also covering quite diverse approaches. Also pre-
ferred by most drug researchers, animal models are not the 
best choice — regardless of ethical aspects — since infection 
processes are species-specific (by the microbial adaption to 
the environment and the immune response). Thus, more 
research efforts are needed to develop and validate alterna-
tive methods, preferably based on human cells and tissues, 
and implementing (patho)physiology-based pharmacokinet-
ics to investigate interrelations between microbe, human and 
therapy either in vitro or in silico [13].
Drug delivery is able to contribute to our overall attempts 
for combatting and preventing the various threats associ-
ated with infectious diseases. Currently, many of these 
approaches are in academia and funded by public resources. 
Clinical translation of promising concepts is a financial chal-
lenge impossible for academia without potent partners. It is 
important to have such translational aspects in view on time 
(e.g., securing intellectual property, planning technologi-
cal approaches   like scale up or biocompatibility of novel 
excipients early). Further, it is pertinent to develop mod-
els for selecting and propagating the most promising anti-
infectives. Institutions, networks, and strategy plans were 
created like GARD-P (https:// gardp. org/), Carb-X (https:// 
carb-x. org/), and BEAM Alliance (https:// beam- allia nce. eu/) 
to foster antibiotic drug discovery and development. Histori-
cally, drug delivery is often seen as a part of “development” 
rather than as “research”. Targeted delivery and transport of 
drugs across biological barriers require an advanced under-
standing of the relevant biological and physicochemical fun-
damentals. Like building an airplane or a spacecraft must 
overcome the laws of gravity, advanced drug delivery goes 
beyond the mere application of well-established principles. 
The development of novel anti-infectives makes it neces-
sary to spend money and time early on to ensure optimized 
delivery and accurate dosing are achieved (otherwise risking 
a short time before resistance development).
Challenges always come with opportunities. The cur-
rent awareness of the threats of infectious disease and 
their impact on modern life may provide an opportunity to 
rethink our priorities and lead to developing contingency 
interventions with greater engagement. Drug delivery will 
play an important role in these interventions. In this spirit, 
we hope you enjoy the science of this special issue collec-
tion where Eastern and Western drug delivery approaches 
to the relentless challenge of infectious disease worldwide 
are highlighted.
In the Western perspective, the issue offers a collection of 
thirteen experimental or review articles. For example, exciting 
developments are discussed by researchers at the University 
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of Copenhagen on emerging nanoparticle pulmonary deliv-
ery systems to treat respiratory tract bacterial infections [14]. 
Thiyagarajan et al. enhance the pulmonary delivery potential 
of antimycobacterial nanopharmaceuticals by spray-drying 
the nanoparticles to form lactose-leucine microparticles with 
potentially more favorable aerodynamic properties [15]. Along 
the same delivery route, the challenge of delivering large anti-
infectious biologics, antibodies, is presented by Mayor et al. 
[16] while Juntke et al. present a novel model of human bron-
chial epithelial cells cultivated at the air–liquid interface (ALI) 
and infected with a Pseudomonas aeruginosa biofilm that 
could have a large impact on the testing of such aerosolized 
anti-infective nanoparticle delivery systems [17]. The use of 
lipid delivery systems and their potential to ameliorate antimi-
crobial therapeutic effects are expounded in Clive Prestidge’s 
“Nano-fats for bugs” review [18] and highlighted again by 
Ryan et al. exploration of solid lipid nanoparticles for delivery 
of dual-acting antimicrobial peptides [19]. Nnamani et al. also 
investigate lipid-based nanogels for the delivery of artemether 
to treat malaria in this issue [20]. Across several of the publica-
tions, and indeed in Albayaty et al. work on fighting infections 
caused by fungal biofilms [21] and Re et al. review on treating 
recurrent candidiasis [22], nanotechnology and drug delivery 
strategies, in the form of lipid or polymeric nanoparticles and 
micelles, show large potential in defeating biofilms of resist-
ant strains. Mucoadhesive polymers are also highlighted by 
Senel et al. to treat fungal infections in the mouth [23]. We 
are reminded of the challenges of treating infection in hos-
pital settings in two reviews in this issue, from researchers at 
John Hopkins University in the USA and at Goethe Univer-
sity Frankfurt, on emerging strategies of local drug delivery to 
combat post-operative infections from implantable biomateri-
als [24] and on the treatment of infected wounds respectively 
[25]. Lastly, from the Western perspective, given the focus 
on vaccine production during the recent pandemic, the issue 
would not be complete without an article highlighting the 
importance of nanotechnology and drug delivery in vaccine 
development. Cordeiro et al. work reports on their novel poly-
saccharide nanoparticles with immunomodulatory properties, 
highlighting their potential in future vaccine development [26].
In the Eastern perspective, the issue offers a collection 
of fifteen relevant research or review papers, contributed 
by world-leading researchers. For example, various bio-
materials have been exploited to exhibit unique functions 
and promote innovations in the field of drug delivery. Meng 
et al. review the applications of chitosan-based systems for 
the treatment of infectious diseases, as well as the design 
considerations including adhesive ability, controlled release 
function, and other physical properties [27]. Skin application 
of chitosan-based hydrogels was reported by Huang et al. 
[28]. Chitosan-based hydrogels showed improved recovery 
of hydrofluoric acid burns with the prevention of skin infec-
tions. These topical hydrogels can be useful for the versatile 
delivery of antibiotics and antiviral drugs for the prevention 
of secondary infections in skin injury. Prabhu et al. stud-
ied injectable mannose-modified chitosan nanoparticles for 
enhanced intracellular delivery of rifampicin to the sites of 
tuberculosis [29], which has been one of the major infectious 
diseases threatening public health in Asia. Due to the intra-
cellular survival pathogenicity of Mycobacterium tubercu-
losis, effective delivery systems could be essential. Chogale 
et al. focused on the development of the dry powder inhaler 
formulation for the treatment of tuberculosis [30].
Stimuli-responsive materials have been shown to achieve 
highly efficient drug delivery and targeted treatment. Wei 
et al. present the ultrasound-responsive polymer-based drug 
delivery systems for biomedical applications with introduc-
tion of the stimulation mechanism and typical formulations, 
including polymeric nanodroplets, micelles, microbubbles, 
and hydrogels [31]. Deng and Liu discuss the potential of 
utilizing inflammation-associated pathological milieu, such 
as oxidative stress, acidic pH, and overexpressed enzymes 
to trigger the release of therapeutic agents from responsive 
drug carriers for improved treatment and management of 
chronic inflammatory diseases [32].
Nanotechnology has been extensively explored for bioappli-
cations including drug delivery and tissue engineering. Yang 
et al. highlight the recent advances in the development of thera-
peutic nanoformulations against various infectious for patho-
gen- and host-targeted antiviral delivery [33]. Fan et al. give 
an overview of antimicrobial nanomedicine ocular infections 
including keratitis and endophthalmitis [34]. DNA-derived 
nanostructures that selectively capture gram-positive bacteria 
were reviewed by Kim et al. [35]. Besides, Wang et al. survey 
the application of titanium dioxide nanotubes as drug carriers 
for infection control and osteogenesis of bone implants [36]. 
Cai et al. review the nanotechnology for physical sterilization 
focusing on topographical nanostructures [37].
Especially with the pandemics of COVID-19, vaccine 
delivery systems have received unprecedented high atten-
tion for the public health of the globe. Vaccine delivery sys-
tems for prevention of infectious diseases are overviewed by 
Kim et al. [38]. This review covers lipid and polymer-based 
non-viral delivery technologies for recently emerged viral 
infectious diseases including COVID-19 and Zika virus. In 
addition, transdermal drug delivery systems such as patches 
and microneedles have emerged as an alternative administra-
tion method with minimal invasion and less pain. Wang et al. 
describe transdermal delivery of antiviral drugs and vaccine 
antigens against COVID-19, influenza, and herpes simplex 
[39]. As transdermal delivery systems, the merits and limi-
tations of transdermal patches and microneedles have been 
discussed. Oh et al. describe a microneedle-assisted vacci-
nation for immunization through the buccal mucosa, which 
demonstrates a high serum IgG titer comparing to traditional 
transmucosal delivery [40].
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The exploration  of infectious disease  detection has 
also attracted tremendous attention especially during the 
ongoing COVID-19 pandemic. Zhang et al. summarize the 
recent advances in self-luminescent systems for the detection 
of bacteria, fungi, and viruses byusing the advantages of 
ATP-derived self-luminescence as the light source [41]. In 
addition, they also provide an overview of self-luminescence 
system-based photodynamic therapy for treating infectious 
diseases.
Collectively, this special issue highlights the diverse 
research work and most advanced progress in the field of 
prevention and treatment of infectious diseases. Although 
several hurdles may remain for translation to clinical trials, 
the experimental delivery technologies presented could pro-
vide a dynamic platform for future pipelines of new drugs 
fighting against infectious diseases. We also hope that these 
important endeavors would provide the opportunity for the 
development and translation of drug delivery systems to 
fight infectious diseases, especially for COVID-19.
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